Caris Life Sciences (NASDAQ: CAI) announced the addition of two AI-powered signatures to its Molecular Tumor Board Report that assess brain metastases risk in breast and lung cancer patients. The new signatures bring the company's total proprietary AI insights to seven.

The signatures were developed using data from 12,994 non-small cell lung cancer cases and 3,371 breast cancer cases with matched survival outcomes. The tools generate predictive scores using whole exome sequencing and whole transcriptome sequencing data from each patient's molecular profile.

Results are displayed as Kaplan-Meier curves to show clinicians the likelihood and rate of brain metastasis development. The signatures are included in reports available when ordering MI Cancer Seek testing at no additional cost.

"Insights from these proprietary Caris AI signatures give us a forward-looking view of which patients may be at elevated risk for brain metastases, allowing us to help guide clinicians to shift from passive surveillance to more proactive monitoring," said David Spetzler, president of Caris Life Sciences.

Caris received FDA approval in November 2024 for MI Cancer Seek, described as the first simultaneous whole exome and whole transcriptome sequencing-based assay with FDA-approved companion diagnostic indications for molecular profiling of solid tumors.

The company operates a database containing molecular profiling data from over 500,000 patients tested with whole exome sequencing and whole transcriptome sequencing. A study is in progress with collaborators from the Caris Precision Oncology Alliance to examine the brain metastases risk prediction capabilities.

The Irving, Texas-based company provides precision medicine services in the United States and international markets through direct operations and distributor partners.